GSK3B and cancer: This synergistic inhibitory treatment catalyses on the varied GSK-3β involvement in multiple signalling pathways to increase DNA damage and impair DNA repair, as well as alter the tumour microenvironment to reduce cell migration, cancer stemness, and metabolic pathways.